Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients.
Intracavernous self-injection of vasoactive drugs is a well accepted therapy for the management of erectile dysfunction in neurogenic disorders. We present the results of a self-injection program in seven MS patients who were admitted in Institut Guttmann of Barcelona and who presented with an insufficient erection. All patients showed an excellent erectile response and had penile rigidity sufficient for sexual intercourse during acceptable time, with minimal complications. A patient reported improvement of erectile capacity so as not to need another cavernously injection for 2-3 months.
D000328:Adult; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010410:Penile Erection; D012646:Self Administration; D012720:Severity of Illness Index; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000209:etiology*
D007004:Hypoglycemic Agents; D007328:Insulin; D010276:Parasympatholytics; D010208:Papaverine